Shares of pre-revenue biopharma Biohaven Pharmaceutical (NYSE: BHVN) dropped nearly 29% this morning after the company reported that one of its lead drug candidates failed to meet both its primary endpoint and key secondary outcome measure in a phase 2/3 trial. The drug candidate, trigriluzole, was the most advanced in the company’s glutamate platform, which targets several rare diseases.